The companies will partner to identify at least two, and possibly three, chromosomal instability (CIN)-related, synthetic lethal targets as drug candidates. The targets to be partnered do not include Volastra’s lead synthetic lethal target—KIF18A, a mitotic kinesin-8 motor protein shown to play a role in promoting the viability of CIN cancer cells. KIF18A regulates chromosome positioning during cell division and is overexpressed in a subset of human cancers . . .
